Hair Health, Hair Loss
Conditions
Brief summary
This clinical trial aims to investigate the effectiveness of two Vitamins Revive hair supplements in promoting hair growth, reducing hair loss, and improving overall hair health. The products under assessment are Hair Nutra Growth and Hair Nutra Boost. The trial will assess the efficacy of the products to induce better hair growth, reduction in hair loss and shedding, increased hair thickness and fullness, and improvement in hair appearance and vitality over a 12-week testing period. Participants will complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12. Participants will also provide photos of their hair at Baseline, Week 4, Week 8, and Week 12.
Interventions
DIETARY_SUPPLEMENTHair Nutra Growth Supplement & Hair Nutra Boost Supplement
Study Initiation (Week 0) to Week 8: Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules. Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water.
DIETARY_SUPPLEMENTHair Nutra Growth
From Week 9 to Week 12: Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water.
Sponsors
Citruslabs
BrandiZone
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Women Aged 30+ Self-reported issues with hair growth, shedding, and thinning Generally healthy - don't live with any uncontrolled chronic disease Must be willing to stop taking any other hair growth supplements or biotin supplements for the duration of the trial In the last three months, has not introduced any new supplements or medications to target hair growth, hair loss, or hair health Individuals must agree to refrain from dyeing their hair in the target interest areas until the study is complete Willing and able to take high-quality photographs of their hairline
Exclusion criteria
* Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders Anyone with known severe allergic reactions Anyone with a known allergy to any of the ingredients Anyone currently using a hair growth supplement Anyone currently using biotin Anyone with scalp or hair diseases including but not limited to alopecia areata (a hair loss disorder leading to patchy bald spots on the head) Women who are pregnant, breastfeeding, or attempting to become pregnant Unwilling to follow the study protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in self-reported rate of hair growth. [Timeframe: Baseline to Week 12] | 12 weeks | Changes in self-reported rate of hair growth will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., Not at all) and 1 representing the least favorable/worst outcome (e.g., Severe). |
| Changes in hair shedding. [Timeframe: Baseline to Week 12] | 12 weeks | Changes in hair shedding will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., Not at all) and 1 representing the least favorable/worst outcome (e.g., Severe). |
| Changes in self-reported rate of hair loss. [Timeframe: Baseline to Week 12] | 12 weeks | Changes in rate of hair loss will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., Not at all) and 1 representing the least favorable/worst outcome (e.g., Severe). Changes in self-reported rate of hair loss |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in participant-percieved overall hair health. [Timeframe: Baseline to Week 12] | 12 weeks | Changes in participants perception of their overall hair health will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., Not at all) and 1 representing the least favorable/worst outcome (e.g., Severe). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes in hair thickness. [Timeframe: Baseline to Week 12] | 12 weeks | Changes in participants' perception of their hair thickness will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., Not at all) and 1 representing the least favorable/worst outcome (e.g., Severe). |
| Changes in hair vitality. [Timeframe: Baseline to Week 12] | 12 weeks | Changes in participants' perception of their hair vitality will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., Not at all) and 1 representing the least favorable/worst outcome (e.g., Severe). |
| Changes in hair softness. [Timeframe: Baseline to Week 12] | 12 weeks | Changes in participants' perception of their hair softness will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., Not at all) and 1 representing the least favorable/worst outcome (e.g., Severe). |
| Changes in hair shine. [Timeframe: Baseline to Week 12] | 12 weeks | Changes in participants' perception of their hair shine will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., Not at all) and 1 representing the least favorable/worst outcome (e.g., Severe). |
Countries
United States
Outcome results
None listed